Evidence map›Paper›PMID 24727605›Full record

ArticleBiosensors & bioelectronics2014

Real-time analysis of the effects of toxic, therapeutic and sub-therapeutic concentrations of digitoxin on lung cancer cells.

R Eldawud, T A Stueckle, S Manivannan, H Elbaz, M Chen, Y Rojanasakul, C Z Dinu

Open access · greenAbstract read
In one paragraph

Article in Biosensors & bioelectronics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

R EldawudDepartment of Chemical Engineering, West Virginia University, WV, United States.
T A StueckleHealth Effects Laboratory Division, National Institute for Occupational Safety and Health, WV, United States; Department of Basic Pharmaceutical Sciences, West Virginia University, WV, United States.
S ManivannanDepartment of Chemical Engineering, West Virginia University, WV, United States.
H ElbazWayne State University School of Medicine, MI, United States.
M ChenDepartment of Basic Pharmaceutical Sciences, West Virginia University, WV, United States.
Y RojanasakulDepartment of Basic Pharmaceutical Sciences, West Virginia University, WV, United States; Mary Babb Randolph Cancer Center Allen Lung Program, West Virginia University, WV, United States. Electronic address: yrojan@hsc.wvu.edu.
C Z DinuDepartment of Chemical Engineering, West Virginia University, WV, United States; Department of Basic Pharmaceutical Sciences, West Virginia University, WV, United States; Mary Babb Randolph Cancer Center Allen Lung Program, West Virginia University, WV, United States. Electronic address: cerasela-zoica.dinu@mail.wvu.edu.
West Virginia University · USWayne State University · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Digitoxin belongs to a naturally occurring class of cardiac glycosides (CG); digitoxin is clinically approved for heart failure and known for its anti-cancer effects against non-small lung cancer cells (NSCLC). However, concerns associated with its narrow therapeutic index and its concentration-dependent mechanism of action are rising. Thus, before digitoxin implementation in designing and developing safer and more effective CG-based anti-cancer therapies, its pharmacological and safety profiles need to be fully elucidated. In this research we used a combinatorial approach to evaluate the anti-cancer mechanisms of digitoxin in real-time. Our approach employed a non-invasive electric cell impedance sensing technique as a proxy to monitor NSCLC behavior post-exposure to toxic, therapeutic and sub-therapeutic concentrations of the drug. By developing structure-function combinatorial relations we showed that digitoxin targets cancer cells in a time and dose-dependant manner by activating pro-apoptotic and anti-proliferative signaling cascades that results in strengthening cellular adhesion and sequestration of key regulatory proliferation protein from the nucleus.

Indexed as

Antineoplastic AgentsApoptosisBiosensing TechniquesCarcinoma, Non-Small-Cell LungCardiotonic AgentsCell AdhesionCell Line, TumorDigitoxinHumansLungLung NeoplasmsSignal TransductionAntineoplastic AgentsCardiotonic AgentsDigitoxinAnti-cancerCell adhesionCell-based sensingDigitoxin

Identifiers

PMID24727605
PMCPMC4739845
OpenAlexW2075041232

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.